Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.53 |
| ▸ | GJB2 | P29033 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cellobiose SCHEMBL9401040 | 0.86 | LGALS8 (0.56) | LGALS8LGALS3LGALS4GJB2 | |
| SCHEMBL17767369 | 0.84 | TLR4 (0.47) | LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL7619250 | 0.83 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| Cellobiose SCHEMBL5358771 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| Maltose SCHEMBL8764715 | 0.83 | GJB2 (0.53) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| Cellobiose SCHEMBL5354201 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| Cellobiose SCHEMBL22034126 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| Cellobiose SCHEMBL7118280 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| Cellobiose SCHEMBL5360199 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| Cellobiose SCHEMBL22034051 | 0.83 | IGF2R (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116498-B1 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS | BODOR LABORATORIES INC (US) | 2018-12-12 | — | — | EP | claimed |
| US-20240002372-A1 | ANTICHOLINERGIC AGENTS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2024-01-04 | — | — | US | disclosed |
| EP-4251608-A1 | ANTICHOLINERGIC AGENTS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116669721-A | Anticholinergic agent | 宁康瑞珠生物制药(珠海)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-110917124-B | Preparation of soft anticholinergic analogues | 博多尔实验仪器公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-110420167-B | Formulations of soft anticholinergic analogs | 博多尔实验仪器公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2022111500-A1 | ANTICHOLINERGIC AGENTS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2022-06-02 | — | — | WO | disclosed |
| US-11034652-B2 | Formulation for soft anticholinergic analogs | BODOR LABORATORIES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10961191-B2 | Formulation for soft anticholinergic analogs | BODOR LABORATORIES, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210078946-A1 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS | BODOR LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| EP-1617833-A4 | COMPOSITIONS AND METHODS FOR TREATING BODY MALODOR AND FUNGAL OVERGROWTH IN MAMMALS | LIGHTHOUSE INNOVATIONS LLC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1617833-A2 | COMPOSITIONS AND METHODS FOR TREATING BODY MALODOR AND FUNGAL OVERGROWTH IN MAMMALS | Lighthouse Innovations, LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004093792-A2 | COMPOSITIONS AND METHODS FOR TREATING BODY MALODOR AND FUNGAL OVERGROWTH IN MAMMALS | LIGHTHOUSE INNOVATIONS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040209954-A1 | Compositions and methods for treating body malodor and fungal overgrowth in mammals | LIGHTHOUSE INNOVATIONS, LLC | 2004-10-21 | — | — | US | disclosed |
| US-6433003-B1 | TOPICALLY ADMINISTERING GLYCOPYRROLATE TO PREVENT SWEATING; SIDE EFFECT REDUCTION | DERMIRA, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6395757-B1 | ADMINISTERING A GLYCOPYRROLATE COMPOUND | DERMIRA, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1123098-A4 | METHOD FOR TREATING HOT FLASHES IN HUMANS | BOBROVE ARTHUR M (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1123098-A1 | METHOD FOR TREATING HOT FLASHES IN HUMANS | BOBROVE, Arthur M. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000012087-A1 | METHOD FOR TREATING HOT FLASHES IN HUMANS | BOBROVE ARTHUR M (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5962505-A | Method for treating hot flashes in humans | DERMIRA, INC. | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961191-B2 | Formulation for soft anticholinergic analogs | GALR3, GALR2, CHRM2 | LGALS8 318/4885LGALS3 306/4885LGALS4 566/4885 |
| US-20210078946-A1 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS | GALR3, GALR2, CHRM2 | LGALS8 318/4885LGALS3 306/4885LGALS4 566/4885 |
| US-20240002372-A1 | ANTICHOLINERGIC AGENTS | CHRM3, CHRM2, CHRM1 | LGALS8 2240/4885LGALS3 1270/4885LGALS4 2992/4885 |
| US-11034652-B2 | Formulation for soft anticholinergic analogs | GALR3, GALR2, CHRM2 | LGALS8 318/4885LGALS3 306/4885LGALS4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.